Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CART19 cells |
Synonyms | |
Therapy Description |
CART19 cells are allogeneic T lymphocytes engineered to express a CD19-targeted chimeric antigen receptor (CAR) containing a CD3 zeta chain and the TNFRSF9 (4-1BB) signaling domain, which may induce antitumor activity (PMID: 21716851). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CART19 cells | CART-19 cells | CD19 Immune Cell Therapy 65 | CART19 cells are allogeneic T lymphocytes engineered to express a CD19-targeted chimeric antigen receptor (CAR) containing a CD3 zeta chain and the TNFRSF9 (4-1BB) signaling domain, which may induce antitumor activity (PMID: 21716851). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02935543 | Phase II | CART19 cells | CART19 in Patient With ALL | Terminated | USA | 0 |
NCT02640209 | Phase I | CART19 cells | Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL) | Terminated | USA | 0 |